Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. reports developments as a clinical-stage siRNA biopharmaceutical company advancing its proprietary INTASYL® gene-silencing technology for immuno-oncology. Company updates center on PH-762, an INTASYL compound designed to silence the PD-1 gene and evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Recurring news themes include PH-762 clinical results, safety and pathology data, nonclinical toxicology work, cGMP clinical-supply manufacturing, regulatory-development steps, financial results, equity financing activity and investor presentations. Coverage also reflects the company's use of self-delivering RNAi technology intended to enhance immune-cell activity against tumor cells without specialized formulation or delivery systems.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced the closing of a registered direct offering of 353,983 shares of common stock at a price of $5.65 per share, generating approximately $2 million in gross proceeds. Concurrently, the company issued unregistered Series A and Series B warrants, each allowing the purchase of up to 353,983 shares with an exercise price of $5.40. The proceeds from this offering will be utilized for the development of immuno-oncology programs, working capital, and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent. The company amended existing warrants to a uniform exercise price of $5.40 from previous higher prices, potentially signaling a strategic move to streamline capital activities.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced a registered direct offering of 353,983 shares at $5.65 each, with expected gross proceeds of approximately $2 million. This offering will close around April 20, 2023, and includes unregistered Series A and B warrants for the same number of shares, each with an exercise price of $5.40. The funds will support the development of immuno-oncology programs and other corporate needs. H.C. Wainwright & Co. is the exclusive placement agent. The offering is part of a 'shelf' registration under the SEC regulations established in May 2021. Phio will also amend older warrants to reduce their exercise price to $5.40. This announcement may affect investor perceptions and the company's capital structure.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) presented promising preclinical data at the AACR Annual Meeting 2023, showcasing the efficacy of its dual-targeting INTASYL therapy targeting PD-1 and CTLA-4 in mouse models of colon cancer. This innovative approach demonstrated enhanced anti-tumor activity compared to single-target therapies while maintaining a favorable safety profile. Dr. Mary Spellman emphasized the potential of intratumoral administration to mitigate the high incidence of immune-related adverse events associated with systemic treatments. This breakthrough could represent a significant advancement in immuno-oncology, reflecting Phio's commitment to developing effective cancer therapies.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced new findings from a preclinical study, revealing that its investigational drug mPH-762 induces anti-tumor responses through immune system activation. The study, showcased at the AACR Annual Meeting 2023, demonstrated that mPH-762, when administered intratumorally, generates systemic CD8 T cells that combat untreated tumors, indicating an 'abscopal effect'. Dr. Mary Spellman noted that these results support the clinical use of PH-762, which is currently in a phase 1b trial for advanced melanoma. Additionally, the approach may reduce adverse effects commonly associated with systemic PD-1 inhibition.